News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Micron near $905 after sharp rebound.
  • Micron's fundamentals—$75.10 EPS, ~$59B FCF, ~$1.02T market cap—support upside if AI memory shortages persist.
  • Micron below short-term moving averages and showing bearish momentum.
  • Micron pitched as a tactical long with defined entry, stop and 180-trading-day horizon.
  • Cadence gaining pricing power as semiconductor design complexity and AI needs make EDA more valuable.
  • Cadence's $89.7B market cap, recurring cash flow and double-digit growth underpin an asymmetric long with risk controls.

Latest Articles

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics, a biotechnology firm focused on targeted genetic medicines, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The company will present its RedTail platform and lead candidate CLD-401, aimed at treating metastatic cancers, particularly non-small cell lung cancer and head and neck can…

Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure

Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure

Amwell (NYSE: AMWL) announced that the Department of Veterans Affairs (VA) has issued a Letter of Intent to deploy Amwell's virtual health platform across the VA enterprise to modernize its digital health infrastructure. The VA's selection follows a comprehensive evaluation highlighting Amwell's scalable video consultation capabilities, interoperab…

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

BioAge Labs has dosed the first participant in its Phase 2 QUELL-DME trial, evaluating the novel oral NLRP3 inhibitor BGE-102 for diabetic macular edema treatment. The trial, involving approximately 180 participants, assesses BGE-102 as monotherapy and in combination with anti-VEGF therapy, targeting improvements in visual acuity with topline resul…

Judge Tightens Constraints on Work at Proposed Trump Arch Near Arlington

Judge Tightens Constraints on Work at Proposed Trump Arch Near Arlington

A federal judge has ordered the administration to provide at least 48 hours' notice before engaging in any activity at the site of a proposed 250-foot (76-meter) triumphal arch near Arlington National Cemetery, with an exception for narrowly defined archaeological investigations under the National Historic Preservation Act. The decision follows the…

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Dyne Therapeutics announced that it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial studying z-basivarsen (DYNE-101) for treating Myotonic Dystrophy Type 1 (DM1) at two major upcoming neuromuscular medical meetings. The data include pooled dose group results versus a natural history cohort and updated safety informat…

Oportun Names Bill Franklin as Chief Financial Officer

Oportun Names Bill Franklin as Chief Financial Officer

Oportun, a Nasdaq-listed financial services firm, announced the appointment of Bill Franklin as Chief Financial Officer. Franklin brings over 20 years of experience in financial leadership, including key roles at Discover Financial Services. His expertise is expected to drive Oportun's financial strategy and support its mission of empowering member…

Solaris Energy Infrastructure Raises EBITDA Targets, Shares Tick Higher

Solaris Energy Infrastructure Raises EBITDA Targets, Shares Tick Higher

Solaris Energy Infrastructure (NYSE: SEI) reported raised Adjusted EBITDA guidance for the third and fourth quarters of 2026 and provided an initial projection for the first quarter of 2027. The stock climbed about 6% on the news as the company cited stronger contributions from core power services and better-than-expected results from recently acqu…

Rigetti Shares Jump After $100 Million CHIPS Act Award Becomes Binding

Rigetti Shares Jump After $100 Million CHIPS Act Award Becomes Binding

Rigetti Computing's stock jumped in pre-market trading after the company finalized a $100 million CHIPS Act award from the U.S. Department of Commerce. The binding agreement, executed through a Rigetti subsidiary, funds three R&D initiatives aimed at overcoming scaling bottlenecks in superconducting quantum hardware and includes a minority, non-con…

Raymond James Upgrade and CEO Appearance Propel Airbnb Higher in Pre-Market

Raymond James Upgrade and CEO Appearance Propel Airbnb Higher in Pre-Market

Airbnb shares climbed 0.6% in pre-market trading after Raymond James elevated the stock from Market Perform to Outperform and assigned a $200 price target, citing an "AI Founder Mode" thesis. The upgrade, paired with CEO Brian Chesky's scheduled presentation at the Goldman Sachs Communacopia + Technology Conference, and solid Q2 2026 results are ci…